HealthStream, Inc.
NASDAQ:HSTMMedical - Healthcare Information Services
-$0.34 today
- Market cap
- $831.60M
- Beta
- 0.47
- P/E (TTM)
- 37.8
- EPS (TTM)
- $0.68
- Dividend yield
- 0.51%
Volume 0.38M
Average 0.25M
HSTM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
HealthStream, Inc.NASDAQ: HSTM
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $13.61M rose 12.9% year over year, ahead of the +7.4% change in trailing-twelve-month research & development. Sequentially, it fell 7.8% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Research & development amounted to 16.8% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.9% holds above the trailing-twelve-month pace of +7.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 50.98M USD
- Year-over-year change
- +4.3%
- 4-year CAGR
- +5.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.98M | +4.3% |
| FY2024 | 2024-12-31 | 48.89M | +7.4% |
| FY2023 | 2023-12-31 | 45.54M | +2.9% |
| FY2022 | 2022-12-31 | 44.28M | +6.3% |
| FY2021 | 2021-12-31 | 41.66M | — |
Research & Development vs competitors
How HSTM compares with its peers on the latest reported figures
- HSTM's LTM Mar 2026 research & development of $52.54M is the 3rd highest of the 10 companies compared; the peer median is $7.56M.
- Its year-over-year change of +7.4% is the 2nd highest of 7, against a peer median of -16.5%.
- Research & development amounts to 16.9% of revenue for HSTM, versus a peer median of 6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $117.98M | -1.9% | +10.0% | 23.8% | |
| LTM Mar 2026 | $63.14M | -22.5% | -19.3% | 26.6% | |
| LTM Mar 2026 | $52.54M | +7.4% | +4.8% | 16.9% | |
| LTM Mar 2026 | $44.26M | -24.0% | -13.0% | 14.6% | |
| LTM Mar 2026 | $31.97M | -10.4% | -0.1% | 13.4% | |
| LTM Mar 2026 | $7.56M | +84.3% | +13.2% | 6.1% | |
| LTM Mar 2026 | $7.53M | -25.4% | +35.2% | 3.4% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HSTM) | $7.56M | -16.5% | +5.0% | 6.1% | |
Competitors are the stored peer set for HSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 256.71M | 266.83M | 279.06M | 291.65M | 304.06M |
| Cost of Revenue | 91.03M | 91.14M | 95.02M | 97.94M | 107.21M |
| Gross Profit | 165.68M | 175.68M | 184.04M | 193.71M | 196.86M |
| Gross Margin | 64.5% | 65.8% | 65.9% | 66.4% | 64.7% |
| Research & Development | 41.66M | 44.28M | 45.54M | 48.89M | 50.98M |
| Selling, General & Admin | 79.15M | 81.01M | 81.41M | 82.29M | 82.16M |
| Operating Expenses | 157.62M | 163.23M | 168.02M | 172.42M | 176.62M |
| Depreciation & Amortization | 36.81M | 37.95M | 41.08M | 41.24M | 43.48M |
| EBITDA | 44.58M | 53.53M | 59.59M | 66.05M | 66.7M |
| EBITDA Margin | 17.4% | 20.1% | 21.4% | 22.6% | 21.9% |
| Operating Income | 8.06M | 12.45M | 16.02M | 21.29M | 20.24M |
| Operating Margin | 3.1% | 4.7% | 5.7% | 7.3% | 6.7% |
| Interest Income | 0 | 444K | 2.36M | 3.83M | 3.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (289K) | 3.14M | 2.49M | 3.52M | 2.98M |
| Income Before Tax | 7.77M | 15.59M | 18.51M | 24.8M | 23.22M |
| Pre-Tax Margin | 3.0% | 5.8% | 6.6% | 8.5% | 7.6% |
| Income Tax Expense | 1.92M | 3.49M | 3.3M | 4.8M | 4.88M |
| Net Income | 5.85M | 12.09M | 15.21M | 20.01M | 18.34M |
| Net Margin | 2.3% | 4.5% | 5.5% | 6.9% | 6.0% |
| EPS (Basic) | 0.19 | 0.39 | 0.50 | 0.66 | 0.61 |
| EPS (Diluted) | 0.18 | 0.39 | 0.50 | 0.66 | 0.61 |
| Weighted Avg Shares | 31.53M | 30.65M | 30.57M | 30.39M | 30.02M |
| Weighted Avg Shares (Diluted) | 31.62M | 30.72M | 30.67M | 30.54M | 30.14M |
HealthStream, Inc.
NASDAQ:HSTM
Intrinsic Alpha fair value
Locked
Current Price
$27.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.